Document is current
Any future updates will be listed below
-
Authors
Cebulla, Gina https://orcid.org/0009-0009-3091-259X
Hai, Ling
Warnken, Uwe
Güngör, Cansu
Hoffmann, Dirk C.
Korporal-Kuhnke, Mirjam
Wildemann, Brigitte
Wick, Wolfgang https://orcid.org/0000-0002-6171-634X
Kessler, Tobias https://orcid.org/0000-0001-8350-7074
Weiler, Markus https://orcid.org/0000-0002-8942-7662
-
Funding
Funding for this research was provided by:
Deutsches Krebsforschungszentrum
Bundesministerium für Bildung und Forschung
Deutsches Krebsforschungszentrum (DKFZ)
- License Information
-
More Information
Article History
Received: 3 November 2024
Revised: 21 January 2025
Accepted: 10 February 2025
First Online: 14 March 2025
Declarations
:
: G. Cebulla, L. Hai, U. Warnken, C. Güngör, and D.C. Hoffmann report no disclosures.M. Korporal-Kuhnke reports speaker honoraria from Novartis, BMS and Merck, all outside the present work. B. Wildemann reports research support from DFG, BMBF, Dietmar-Hopp-Stiftung, Klaus-Tschita-Stiftung, Merck, Novartis, Roche, and speaker honoraria form Alexion, Merck, INSTAND, Novartis, and Roche, all outside the present work. W. Wick reports consulting honoraria outside the present work from Enterome, Roche, and Servier. T. Kessler reports no disclosures. M. Weiler reports consultant honoraria from Biogen and Roche, and speaker honoraria and travel support for conference attendance from Biogen, all outside the present work.
: This prospective exploratory monocentric study was approved by the institutional ethics board (University of Heidelberg; S-554/2018). The study conforms with The Code of Ethics of the World Medical Association (Declaration of Helsinki).
: Written informed consent was obtained from all individual participants included in the study.
: Consent to publish was obtained from all participants.
